Ifi205 Protein Target Identification for Neuropathic Pain Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain management strategies face challenges with side effects and resistance issues from traditional analgesics, and there is a need for new approaches and targets for pain therapy, particularly in treating chronic pain.
Innovation Solution
The method involves using a test system comprising Ifi205 nucleic acid or protein to identify compounds involved in pain by detecting significant effects of test compounds on the system, which can lead to the development of therapeutic agents for pain treatment, including neuropathic pain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional analgesics are used for pain treatment, then pain relief is achieved, but side effects and resistance occur
Solution Approach 1:
The patent changes the molecular target parameter from traditional analgesic targets to the Ifi205 protein target. By identifying and targeting Ifi205, which is specifically involved in neuropathic pain pathways, the invention achieves pain relief through a different molecular mechanism, thereby avoiding the side effects and resistance associated with traditional analgesics that target conventional pathways.
2Reliability
If new pain therapy targets are developed, then treatment effectiveness improves, but development complexity increases
Solution Approach 1:
The patent performs preliminary identification and characterization of the Ifi205 target before drug development. By first establishing Ifi205 as a valid therapeutic target through genetic studies and functional analysis, the invention creates a solid foundation that simplifies subsequent drug discovery efforts. This preliminary validation reduces the overall development complexity compared to starting de novo target identification.
3Productivity
If Ifi205-based test systems are used for compound identification, then novel pain compounds are discovered, but testing complexity increases
Solution Approach 1:
The patent uses the Ifi205 protein or its nucleic acid as an intermediary element in the test system. This intermediary serves as a specific binding target that mediates the interaction between test compounds and the pain pathway. By using this well-defined intermediary, the system achieves high specificity in compound identification while managing complexity through a focused, single-target approach rather than complex multi-parameter systems.
Data Source
Figure 1
Figure 2a
Figure 2b
AI summary
The present invention relates to a method of identifying a compound involved in pain, the use of Ifi205 nucleic acid or Ifi205 protein for identifying a compound involved in pain as well as methods of diagnosing algesia involving the same.